A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

May 24, 2024

Study Completion Date

December 31, 2026

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmsChronic Myelomonocytic LeukemiaMyelofibrosis

Interventions

DRUG

Ipilimumab

Ipilimumab is an antibody that acts against CTLA-4

BIOLOGICAL

CD25hi Treg depleted DLI

Donor lymphocyte product

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER